ODEFSEY SIDE EFFECTS
- Generic Name: emtricitabine, rilpivirine, and tenofovir alafenamide fixed-dose combination tablets
- Brand Name: Odefsey
SIDE EFFECTS
The following adverse reactions are discussed in other sections of the labeling:
- Severe Acute Exacerbations of Hepatitis B
- Skin and Hypersensitivity Reactions
- Hepatotoxicity
- Depressive Disorders
- New Onset or Worsening Renal Impairment
- Lactic Acidosis/Severe Hepatomegaly with Steatosis
- Immune Reconstitution Syndrome
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug (or a drug given in various combinations with other concomitant therapy) cannot be directly compared to rates in the clinical trials of another drug (or drug given in the same or different combination therapy) and may not reflect the rates observed in practice.
Adverse Reactions In Clinical Trials Of ODEFSEY In Virologically-Suppressed Adult Subjects With HIV-1 Infection
The safety of ODEFSEY in virologically-suppressed adults is based on Week 48 data from two randomized, double-blinded, active-controlled clinical trials, 1160 and 1216, that enrolled 1505 adult subjects who were virologically-suppressed for at least 6 months. Both trials were designed to compare switching to ODEFSEY to maintaining efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) or emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) in Trials 1160 and 1216, respectively. A total of 754 subjects received one tablet of ODEFSEY daily.
The most common adverse reactions (all Grades) reported in at least 2% of subjects in the ODEFSEY group across Trials 1216 and 1160 were headache and sleep disturbances (Table 1). Over 98% of the adverse reactions in the ODEFSEY group were of mild to moderate intensity. The proportion of subjects who discontinued treatment with ODEFSEY due to adverse events, regardless of severity, was 2% compared to 1% for FTC/RPV/TDF and 2% for EFV/FTC/TDF.
Table 1 : Adverse Reactionsa (All Grades) Reported in ≥1% of HIV-1 Infected Virologically-Suppressed Adults in Trial 1160 or Trial 1216 (Week 48 analysis)
Adverse Reaction | Trial 1160 | Trial 1216 | ||
ODEFSEY (N=438) |
EFV/FTC/TDF (N=437)b |
ODEFSEY (N=316) |
FTC/RPV/TDF (N=313)b |
|
Headache | 2% | 1% | 0 | 1% |
Sleep Disturbances | 2% | 1% | 0 | <1% |
Flatulence | 1% | <1% | <1% | 1% |
Abnormal Dreams | 1% | 1% | 0 | 2% |
Diarrhea | 1% | 3% | 1% | 2% |
Nausea | 1% | 1% | 1% | 1% |
a Frequencies of adverse reactions are based on all adverse events attributed to study drugs by the investigator. b Data from Trials 1160 and 1216 do not provide an adequate basis for comparison of adverse reaction incidences between ODEFSEY and the FTC/RPV/TDF and EFV/FTC/TDF groups. |
Renal Laboratory Tests
In Trial 1216, the median baseline eGFR was104 mL per minute for subjects who switched to ODEFSEY from FTC/RPV/TDF (N=316) and the mean serum creatinine decreased by 0.02 mg per dL from baseline to Week 48.
In Trial 1160, the median baseline eGFR was 110 mL per minute for subjects who switched to ODEFSEY from EFV/FTC/TDF (N=438), and the mean serum creatinine increased by 0.1 mg per dL from baseline to Week 48.
Bone Mineral Density Effects
Changes in BMD from baseline to Week 48 were assessed by dual-energy X-ray absorptiometry (DXA) in Trials 1216 and 1160.
In Trial 1216, mean bone mineral density (BMD) increased in subjects who switched to ODEFSEY (1.61% lumbar spine, 1.04% total hip) and remained stable or decreased in subjects who remained on FTC/RPV/TDF (0.08% lumbar spine, -0.25% total hip). BMD declines of 5% or greater at the lumbar spine were experienced by 1.7% of ODEFSEY subjects and 3.0% of FTC/RPV/TDF subjects. BMD declines of 7% or greater at the femoral neck were experienced by 0% of ODEFSEY subjects and 1.2% of FTC/RPV/TDF subjects.
In Trial 1160, mean BMD increased in subjects who switched to ODEFSEY (1.65% lumbar spine, 1.28% total hip) and decreased slightly in subjects who remained on EFV/FTC/TDF (-0.05% lumbar spine, -0.13% total hip). BMD declines of 5% or greater at the lumbar spine were experienced by 2.3% of ODEFSEY subjects and 4.9% of EFV/FTC/TDF subjects. BMD declines of 7% or greater at the femoral neck were experienced by 1.4% of ODEFSEY subjects and 3.3% of EFV/FTC/TDF subjects. The long-term clinical significance of these BMD changes is not known.
Serum Lipids
Changes from baseline in total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, and total cholesterol to HDL ratio for Trials 1216 and 1160 are presented in Table 2.
Table 2 : Lipid Values, Mean Change from Baseline Reported in Subjects Receiving ODEFSEY, FTC/RPV/TDF and EFV/FTC/TDF in Trials 1216 and 1160 at 48 Weeks
Trial 1216 | Trial 1160 | |||||||
ODEFSEY N=316 [n=235] |
FTC/RPV/TDF N=314 [n=245] |
ODEFSEY N=438 [n=295] |
EFV/FTC/TDF N=437 [n=308] |
|||||
Baseline mg/dL | Week 48 Changeab | Baseline mg/dL | Week 48 Changeab | Baseline mg/dL | Week 48 Changeab | Baseline mg/dL | Week 48 Changeab | |
Total Cholesterol (fasted) | 176 | + 17 | 171 | 0 | 193 | -7 | 192 | -3 |
HDL- Cholesterol (fasted) | 50 | +3 | 48 | 0 | 56 | -4 | 55 | -2 |
LDL- Cholesterol (fasted) | 111 | + 13 | 108 | + 1 | 118c | -1c | 119 | -1 |
Triglycerides (fasted) | 116 | + 12 | 119 | -9 | 139 | -12 | 133 | +3 |
Total Cholesterol to HDL Ratio | 3.7 | +0.2 | 3.8 | +0.1 | 3.7 | +0.2 | 3.8 | 0 |
a The change from baseline is the mean of within-subject changes from baseline for subjects with both baseline and Week 48 values. b Subjects who received lipid-lowering agents during the treatment period were excluded. c [n=296] for ODEFSEY group in Study 1160 for LDL-Cholesterol (fasted) |
Adverse Reactions In Clinical Trials Of RPV-Containing Regimens In Treatment-Naive Adult Subjects With HIV-1 Infection
In pooled 96-week trials of antiretroviral treatment-naive HIV-1 infected adult subjects, the most common adverse reactions in subjects treated with RPV+FTC/TDF (N=550) (incidence greater than or equal to 2%, Grades 2-4) were headache, depressive disorders, and insomnia. The proportion of subjects who discontinued treatment with RPV+FTC/TDF due to adverse reactions, regardless of severity, was 2%. The most common adverse reactions that led to discontinuation in this treatment group were psychiatric disorders (1.6%) and rash (0.2%). Although the safety profile was similar in virologically-suppressed adults with HIV-1 infection who were switched to RPV and other antiretroviral drugs, the frequency of adverse events increased by 20% (N=317).
Adverse Reactions In Clinical Trials Of FTC+TAF With EVG+COBI In Treatment-Naive Adult Subjects With HIV-1 Infection
In pooled 48-week trials of antiretroviral treatment-naive HIV-1 infected adult subjects, the most common adverse reaction in subjects treated with FTC+TAF with EVG+COBI (N=866) (incidence greater than or equal to 10%, all grades) was nausea (10%). In this treatment group, 0.9% of subjects discontinued FTC+TAF with EVG+COBI due to adverse event. Antiretroviral treatment-naive adult subjects treated with FTC+TAF with EVG+COBI experienced mean increases of 30 mg/dL of total cholesterol, 15 mg/dL of LDL cholesterol, 7 mg/dL of HDL cholesterol and 29 mg/dL of triglycerides after 48 weeks of use.
Renal Laboratory Tests
In two 48-week trials in antiretroviral treatment-naive HIV-1 infected adults treated with FTC+TAF with elvitegravir (EVG) plus cobicistat (COBI) (N=866) with a median baseline eGFR of 115 mL per minute, mean serum creatinine increased by 0.1 mg per dL from baseline to Week 48.
In clinical trials of FTC+TAF with EVG+COBI in treatment-naive subjects and in virologically-suppressed subjects switched to FTC+TAF with EVG+COBI with estimated creatinine clearance greater than 50 mL per minute, renal serious adverse events or discontinuations due to renal adverse reactions were encountered in less than 1% of participants treated with FTC+TAF with EVG+COBI.
In a 24-week trial in adults with renal impairment (baseline eGFR 30 to 69 mL per minute) who received FTC+TAF with EVG+COBI (N=248), mean serum creatinine was 1.5 mg per dL at both baseline and Week 24. FTC+TAF with EVG+COBI was permanently discontinued due to worsening renal function in two of 80 (3%) subjects.
Bone Mineral Density Effects
In the pooled analysis of two 48-week trials of antiretroviral treatment-naive HIV-1 infected adult subjects, bone mineral density (BMD) from baseline to Week 48 was assessed by dual-energy X-ray absorptiometry (DXA). Mean BMD decreased from baseline to Week 48 by -1.30% with FTC+TAF with EVG+COBI at the lumbar spine and -0.66% at the total hip. BMD declines of 5% or greater at the lumbar spine were experienced by 10% of FTC+TAF with EVG+COBI subjects. BMD declines of 7% or greater at the femoral neck were experienced by 7% of FTC+TAF with EVG+COBI subjects. The long-term clinical significance of these BMD changes is not known.
Adverse Reactions In Clinical Trials In Pediatric Subjects With HIV-1 Infection
In an open-label 48-week trial of 36 antiretroviral treatment-naive HIV-1 infected pediatric subjects 12 to less than 18 years old (weighing at least 32 kg) treated with 25 mg per day of RPV and other antiretrovirals, the most common adverse reactions were headache (19%), depression (19%), somnolence (14%), nausea (11%), dizziness (8%), abdominal pain (8%), vomiting (6%) and rash (6%).
In a 24-week, open-label trial of 23 antiretroviral treatment-naive HIV-1 infected pediatric subjects aged 12 to less than 18 years old (weighing at least 35 kg) who received FTC+TAF with EVG+COBI, the safety of this combination was similar to that of adults. Among these pediatric subjects, mean BMD increased from baseline to Week 24, +1.7% at the lumbar spine and +0.8% for the total body less head. Mean changes from baseline BMD Z-scores were -0.10 for lumbar spine and -0.11 for total body less head at Week 24. Two subjects had significant (greater than 4%) lumbar spine BMD loss at Week 24.
Postmarketing Experience
The following adverse reactions have been identified during postmarketing experience in patients receiving RPV or TAF-containing regimens. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Rilpivirine
Metabolism And Nutrition Disorders
Weight increased
Skin and Subcutaneous Tissue Disorders
Severe skin and hypersensitivity reactions including DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms)
Renal And Urinary Disorders
Nephrotic syndrome
Tenofovir alafenamide
Skin And Subcutaneous Tissue Disorders
Angioedema, urticaria, and rash
Renal And Urinary Disorders
Acute renal failure, acute tubular necrosis, proximal renal tubulopathy, and Fanconi syndrome.
SRC: NLM .